JPTRM Vol. 13 No. 1 (June 2025)

Browse

Recent Submissions

Now showing 1 - 11 of 11
  • Item
    Role of AI in Drug Discovery
    (Chitkara University Publications, 2026-01-09) Deependra Singh
    Background: The pharmaceutical industry is undergoing rapid digital transformation, generating vast and complex datasets that challenge traditional drug discovery workflows. Artificial intelligence (AI) has emerged as a powerful solution capable of processing large-scale clinical, biological, and chemical information with high precision. Its ability to learn from data, uncover hidden patterns, and automate complex tasks positions AI as a transformative force in modern drug development. Objective: This editorial, through an AI lens in drug discovery, demonstrates the significance of AI applications in target identification, hit generation, lead optimization, predictive toxicology, ADMET profiling, and clinical trial design, and the issues and ethical considerations. The difficulties were acknowledged. Results: AI showed massive power in foreseeing drug–target interactions, virtually testing millions of compounds, and creating new chemical structures with better pharmacological profiles. Deep learning techniques were far superior to conventional machine learning methods when predicting ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. The use of AI to perform virtual screening and generate modeling rapidly led to the identification of new drug candidates, while clinical trial design was improved through data-driven algorithms enabling enhanced patient stratification and adaptive protocol utilization. Moreover, AI techniques allowed for the earliest possible toxicity prediction, thus lowering last-stage failures and overall development costs. Conclusion: AI is a significant paradigm shift in drug discovery, which means therapeutics will be developed in a shorter period, at a lower cost, and with higher accuracy. However, the maximum benefit of AI can be achieved only if the technical, ethical, and regulatory challenges are solved through collaborative, transparent, and safe usage of AI-driven innovation facilitation frameworks.
  • Item
    Pharmacological Advances in Targeting Neuroinflammation for Alzheimer’s Disease
    (Chitkara University Publications, 2026-01-09) Kunal
    Background: Alzheimers disease AD is a progressive neurodegenerative disorder characterized by synaptic dysfunction neuronal loss and cognitive decline. Increasing evidence identifies chronic neuroinflammation as a central pathogenic mechanism in AD driven by amyloid beta accumulation. Purpose: The purpose of this review is to critically examine recent pharmacological advances targeting neuroinflammatory mechanisms in AD with emphasis on molecular signaling pathways glial activation dynamics and emerging disease modifying therapeutic strategies. Methods: A comprehensive literature survey was conducted using PubMed Web of Science and Google Scholar to identify relevant preclinical and clinical studies focusing on neuroinflammation targeted interventions in AD. Evidence related to cytokine and eicosanoid signaling inflammasome activation microglial immunoreceptors nonsteroidal anti inflammatory drugs biologics and nanotechnology based drug delivery systems was systematically analyzed. Results: Mechanistic studies demonstrate that pharmacological modulation of microglial phenotypes inhibition of pro inflammatory mediators TNF alpha IL 1 IL 6 and targeting pathways such as NF kappa B NLRP3 inflammasome p38 MAPK JAK STAT and TREM2 can attenuate neuroinflammatory cascades and reduce amyloid beta and tau associated neurotoxicity. However clinical translation remains inconsistent due to limited blood brain barrier permeability off target toxicity and patient heterogeneity. Advanced nanocarrier based delivery systems and intranasal strategies show promise in improving brain bioavailability and therapeutic precision. Conclusion: Targeting neuroinflammation represents a mechanistically robust avenue for disease modification in AD. Future therapeutic success will likely depend on integrated multimodal strategies combining precise inflammatory pathway modulation with advanced brain targeted drug delivery and biomarker guided patient stratification.
  • Item
    Review of Phytochemicals with Anti-Diabetic Potential: Plant Sources and Mechanism
    (Chitkara University Publications, 2025-12-20) Leena Parte; Vaishali Somani; Mrunal Ghag Sawant
    Background: Phytochemicals, the bioactive compounds found in plants, have garnered substantial attention for their potential health benefits. This review delves into the multifaceted therapeutic applications of phytochemicals, particularly in the management of diabetes and its associated complications. Purpose: The review highlights the intricate tapestry of phytochemical interventions, exploring their diverse roles in addressing various aspects of diabetes care. This article delves into the potential side effects and risks associated with the use of phytochemicals, emphasizing the importance of a comprehensive assessment of their safety profile. Methods: To accomplish these objectives, literature has been surveyed from PUBMED, MEDLINE, EMBASE, etc. like search engines, for detailed knowledge about phytochemicals in the management of diabetes and its complications. Result: Various studies have meticulously examined the potential adverse effects and risks intertwined with phytochemicals, underscoring the need for careful consideration in their therapeutic applications. Conclusion: The review explores the diverse therapeutic applications and uses of anti-diabetic phytochemicals, such as the clinical applications of berberine and the therapeutic potential of Stevia rebaudiana Bertoni extracts. The review highlights the importance of continued research and exploration in this burgeoning field to unlock the full potential of phytochemicals in the management of diabetes and its complications.
  • Item
    Formulation, Optimization, and Characterization of Hepatoprotective Polyherbal Tablet
    (Chitkara University Publications, 2025-12-20) Kamaljeet; Rameshwar Das; Priyanka Kriplani; Prabhjot Kaur
    Background: Liver cirrhosis is a liver disease with a high mortality rate worldwide, and antifibrotic drugs are generally used for alleviating symptoms, but there are still limitations of current therapies. Research is going on new therapies including herbals for management of cirrhosis. Objective: Literature-based research identifies curcumin, hesperidin, Aegle marmelos (bael), Solanum nigrum (black nightshade), and Silybum marianum (milk thistle) as hepatoprotective phytoconstituents and herbs. The current study aims to develop and evaluate a hepatoprotective polyherbal tablet. Methods: Tablets were prepared using the direct compression method utilizing polymers including microcrystalline cellulose, starch, etc. Response surface methodology (central composite design) was used for optimizing formulation, taking hardness and disintegration time as dependent variables. The prepared formulations were characterized using parameters including weight variation, friability, thickness, percentage drug release, etc. Furthermore, formulations were evaluated for release kinetics studies. Results: Optimized formulation (F14) revealed percentage drug release from 71.57–94.91%. Furthermore, other parameters were also found to be satisfactory. Results from kinetics study revealed that F14 followed the Hinton-Crowell model with non-fickian release mechanism. Conclusion: Polyherbal hepatoprotective tablets can be used for sustained delivery of polyherbs as an alternative therapy for management of liver cirrhosis and hepatoprotective action. Furthermore, pre-clinical and clinical studies should be done for better applicability.
  • Item
    Box-Behnken Optimized Olmesartan Sublingual Tablets: A Quality by Design Study
    (Chitkara University Publications, 2025-11-24) Deepak Joshi; Pawandeep Shukla; Naveen Kumar Choudhary
    Background: Heart failure is a progressive cardiovascular condition associated with high morbidity and mortality. Although Olmesartan, an angiotensin II receptor antagonist, is effective in managing heart failure, its conventional oral route is limited by poor solubility and variable bioavailability. Purpose: This study aimed to develop a fast-dissolving sublingual tablet of Olmesartan using a Quality by Design (QbD) framework, integrating Box–Behnken Design (BBD) optimization with ex vivo permeation analysis to enhance systemic absorption. Methods: Three critical formulation variables—Sodium Starch Glycolate (SSG), Crospovidone (CP), and Croscarmellose Sodium (CCS)—were evaluated for their effect on disintegration time (DT) and cumulative drug release (CDR). Result: The optimized formulation (OOSF-18), containing 9 mg SSG, 9 mg CP, and 6.44 mg CCS, exhibited a DT of 33.33 s and 92.33% CDR, with strong model predictability (adjusted R² = 0.9961 for DT and 0.9806 for CDR). Ex vivo permeation through porcine mucosa reached 89.76% within 10 min, indicating rapid transmucosal delivery potential. Stability studies confirmed formulation robustness over six months. Conclusion: This combined QbD permeation strategy demonstrates a novel and efficient approach for improving Olmesartan’s bioavailability and offers translational potential for rapid-acting sublingual antihypertensive therapy.
  • Item
    Next Generation Probiotics and Postbiotics: Modulating the Gut Brain Axis in Alzheimer’s Disease
    (Chitkara University Publications, 2025-11-24) Mariyam Hussain; Mohammad Ikram
    Background: Alzheimer’s disease is a progressive neurodegenerative condition involving cognitive impairment, amyloid β deposition, inflammation, and oxidative stress. The gut-brain axis plays a crucial role in neurological health, as gut microbiota influence brain function through various mechanisms, including immune, metabolic, and neuronal pathways. Probiotics have been known to modulate gut microbiota and enhance cognitive effects in Alzheimer’s disease for a long time. However, next-generation probiotics and postbiotics present more specific and promising methods to curtail neuroinflammation and amyloid pathology. Purpose: This review evaluates the potential of next-generation probiotics and postbiotics in Alzheimer’s disease, focusing on their neuroprotective mechanisms, safety, preclinical efficacy, and translational prospects. Method: We conducted a comprehensive literature search using databases such as PubMed, Google Scholar, and Scopus, focusing on studies published up to 2025. Relevant preclinical and clinical studies were screened, and data on mechanism, efficacy, and translational potential were summarised. Result: Evidence indicates that next-generation probiotics restore gut microbial equilibrium, decrease pro-inflammatory cytokines, promote mitophagy, and fortify the intestinal and blood-brain barriers. These actions enhance cognition, decrease amyloid and tau pathology, and safeguard neurons. Postbiotics have comparable neuroprotective actions, with additional benefits of stability and ease of standardisation. Challenges to clinical translation include variability in formulation, poor understanding of gut-brain interactions, degradation during passage through the gastrointestinal tract, and interindividual variability in the composition of the microbiome. Conclusion: Modulation of the gut-brain axis through next-generation probiotics and postbiotics is a promising multi-targeted approach for Alzheimer’s disease, conferring neuroprotection and potentially disease-modifying effects. Future research will include the creation of targeted NGP strains, isolation of neuroactive postbiotic compounds, concurrent use of microbiome-derived therapies with standard treatment of AD, and tailoring interventions according to personalised gut profiles. These strategies can potentially boost cognitive performance, retard disease progression, and enhance quality of life for AD patients.
  • Item
    A Brief Review of Pharmacoeconomics and Its Importance in Healthcare
    (Chitkara University Publications, 2025-10-20) Arti Saini; Shivam Sharma
    Background: Assessing health interventions today requires the use of economic knowledge due to the growing complexity and high cost of healthcare. Pharmacoeconomics, a branch of health economics, assesses the value of pharmaceutical goods and services by weighing their costs and benefits. Pharmacoeconomic analysis plays a critical role in supporting evidence-based decision-making and policy-making as healthcare expenditures throughout the globe continue to grow. Purpose: The objective of this study is to provide a concise overview of pharmacoeconomics, its primary methodologies, and its growing significance within healthcare systems. Methods: This literature review, covering publications from 2014 to 2025, analyzed peer-reviewed articles, policy documents, and textbooks on pharmacoeconomics. The review employed comparative frameworks such as cost minimization, cost-effectiveness, cost-utility, and cost-benefit analyses. Results: Pharmacoeconomic analysis is increasingly being included in national and international healthcare systems to ensure efficient resource management. It significantly influences the evaluation of rival treatment options and the judgments about medication reimbursement. Common methodologies encompass cost-effectiveness and cost-utility evaluations, among others. Countries such as the UK, Canada, and Australia have institutionalized pharmacoeconomic evaluations through the establishment of organizations like the National Institute for Health and Care Excellence (NICE), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Pharmaceutical Benefits Advisory Committee (PBAC). Conclusion: Pharmacoeconomics is a crucial component of the modern healthcare landscape, facilitating the optimal allocation of limited financial resources to enhance health outcomes. It assists policymakers, physicians, and payers in making decisions informed by costs and clinical outcomes. As healthcare costs continue to rise, the role of pharmacoeconomics in policymaking and practice will become increasingly essential.
  • Item
    Reprogramming Chronic Care: AI-Driven Digital Therapeutics for a Connected, Personalized and Equitable Health Future
    (Chitkara University Publications, 2025-10-20) Soumarshi Das; Ravinder Singh
    Background: Non-communicable diseases such as diabetes, cardiovascular disease, and mental disorders contribute to 74% of global annual deaths, creating a major strain on healthcare systems. Conventional episodic care models are inadequate for continuous management, highlighting the need for innovative solutions. Purpose: This review systematically evaluates the role of AI-powered Digital Therapeutics (DTx) in chronic disease management, examining clinical evidence, therapeutic outcomes, regulatory frameworks, and future integration with multidisciplinary healthcare systems, with a focus on low- and middle-income settings such as India. Methods: A comprehensive literature search of clinical trials, meta-analyses, and real-world studies was conducted. Regulatory frameworks like the FDA’s Software as a Medical Device (SaMD) and India’s Ayushman Bharat Digital Mission (ABDM) were analyzed to assess the positioning of Digital Therapeutics (DTx) in healthcare systems. Results: Digital therapeutics (DTx) showed significant advantages in chronic disease management: HbA1c reduction of 0.67% in Type 2 Diabetes patients, improved hypertension control with 84% of patients maintaining sustained blood pressure control over three years, and PHQ-9 score reductions by 7.3 points in depression. The AI-driven DTx platform provided real-time adaptive interventions using digital biomarkers and phenotyping. Despite these outcomes, widespread adoption faces challenges from low digital literacy, regulatory uncertainty, and inadequate reimbursement structures, especially in India. Conclusion: AI-powered Digital Therapeutics (DTx) offer transformative solutions for chronic disease management by enabling personalized, adaptive care. Integrating DTx with Electronic Health Records (EHRs) enhances clinical decision-making and preventive care, but implementation is hampered by regulatory fragmentation and technological gaps.
  • Item
    Assessment of Self-Medication Pattern During Outbreak of Coronavirus Disease in Himachal Pradesh, a Northwestern Himalayan Region of India
    (Chitkara University Publications, 2025-09-30) Raveen Chauhan; Swati Pundir; Naresh Vashist; Chirag Dhawan; Arun Parashar; Ranjan Kumar
    Background: Self-medication (SM) is a major global health issue, especially in low- and middle-income countries with limited healthcare access. During Coronavirus disease, fear, misinformation, and restricted services worsened the problem. This study examined SM prevalence, patterns, and determinants in Himachal Pradesh, India. Purpose: This research aimed to determine the prevalence, pattern, and awareness of self-medication (SM) during the Coronavirus disease outbreak in the general public when no preventive or curative therapy was available. Methods: A descriptive cross-sectional, web-based survey was carried out from January to May 2021 using a pre-validated questionnaire distributed via social media platforms. Owing to pandemic-related constraints, convenience sampling was employed. Eligible participants were residents of Himachal Pradesh aged ≥18 years who provided informed consent. Respondents with incomplete submissions or reporting multiple drug use for unrelated conditions were excluded. Of 654 initial responses, 527 met the criteria for analysis. Descriptive statistics summarized demographic and clinical data, and chi-square tests assessed associations between categorical variables. Results: Among the 527 respondents, 48.5% were male and 51.5% female; nearly half (48.5%) were aged 25–35 years. Fever (30.4%) was the most frequently reported reason for SM, followed by sore throat (19.4%) and weakness (16.7%). Commonly self-administered medicines included paracetamol (33.6%), azithromycin (21.8%), and doxycycline (14.6%). Only 24% reported obtaining medicines on a physician’s advice, while pharmacies and personal networks were predominant information sources. Chi-square analysis revealed a statistically significant association between education level and drug choice (p < 0.05). Notably, 85% of participants were unaware of the risks of overdose or adverse effects. Conclusion: The study concludes that 24% of respondents took medication on a physician’s advice, while the remaining 76% sought SM. Inappropriate self-medication might result in irrational treatment and serious health issues. Therefore, there is an urgent need to monitor and manage SM-related practices. SM was widely practiced in Himachal Pradesh during the Coronavirus disease pandemic, driven by limited healthcare availability and misinformation. Targeted public health education, stricter regulation of over-the-counter drug sales, and community-level awareness initiatives are essential to address this issue.
  • Item
    Therapeutic Applications And Risks of Papaver Somniferum L. Alkaloids In Cancer Pain And Acute Cardiogenic Pulmonary Oedema
    (Chitkara University Publications, 2025-08-25) Karan Thakur; Shivam Thakur; Abhay Sharma; Khemender Lidoo; Om Kumar; Scindia Kohli; Rupinder Kaur; Amit Sharma; Sarita Jangra
    Background: Papaver somniferum L. (opium poppy) is a historically significant medicinal plant, primarily known for its potent alkaloids such as morphine, codeine, and thebaine. With the global rise in opioid use and misuse, understanding the medical potential and risks of poppy-derived compounds has gained renewed significance, particularly in contexts such as cancer-related pain and acute cardiogenic pulmonary edema (ACPE). Purpose: This review evaluates the efficacy and pharmacological mechanisms of P. somniferum alkaloids, particularly morphine, in managing cancer-related pain and acute cardiogenic pulmonary edema (ACPE), alongside associated risks and regulatory concerns. Method: A literature review was conducted, synthesizing data from peer-reviewed studies sourced from PubMed, Google Scholar, Scopus, and Web of Science, focusing on pharmacological, clinical, and biochemical properties of poppy alkaloids. Results: Morphine effectively controls severe cancer pain (80–90% pain reduction in clinical trials) via mu-opioid receptor modulation but is underutilized due to addiction concerns. In ACPE, morphine reduces preload and anxiety but lacks clear survival benefits, with risks like respiratory depression (10–15% incidence) and drug interactions. Conclusion: While Papaver somniferum-derived morphine remains a cornerstone in palliative pain management, its use in ACPE should be approached cautiously due to unclear survival benefits and notable risks.
  • Item
    Hydrogels in Chronic Wound Care: A Multifaceted Approach to Healing and Regeneration
    (Chitkara University Publications, 2025-08-25) Himanshu Sharma; Sanchit Dhankhar; Vishnu Mittal; Balraj Saini; Pooja Mittal; Akashdeep Singh
    Background: In wealthy nations, 1-2% of people suffer from serious chronic wounds. In India, chronic wounds have a prevalence rate of approximately 4.5 per 1000 individuals, with diabetic foot ulcers and pressure ulcers being the most common. Purpose: Chronic wound treatment is necessary to maintain patients’ physical and emotional well-being and improve quality of life. Numerous methods, including hydrogel dressings, skin grafts, debridement, ultrasound, electromagnetic, and negative pressure wound treatment, may be used to treat chronic wounds. Methods: Recent literature has been surveyed from PUBMED, GOOGLE SCHOLAR, etc., like search engines, for summarizing detailed ongoing developments in the field of hydrogels in chronic wound care. Conclusions: Due to their functional qualities that may be adjusted, hydrogel dressings are a viable and promising solution for accelerating the healing of chronic wounds. These characteristics include biodegradability, adhesion, and bioactivities that are pre-antigenic, antibacterial, and anti-inflammatory. This overview summarizes the various types of chronic wounds, stages of the healing process, and important treatment modalities. The advantages of hydrogel-based dressings for treating chronic wounds are discussed, along with their multifunctional qualities, illustrating their superiority over other dressing types for long-term wound healing.